The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 54 results:
Author Title [ Type(Desc)] Year
Filters: Keyword is Antibodies, Monoclonal, Humanized  [Clear All Filters]
Journal Article
Fotiadou, C., Lazaridou E., Sotiriou E., & Ioannides D. (2012).  Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centre.. J Eur Acad Dermatol Venereol. 26(10), 1298-303.
Pentheroudakis, G., Kotoula V., Kouvatseas G., Charalambous E., Dionysopoulos D., Zagouri F., et al. (2014).  Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.. Clin Breast Cancer. 14(5), 330-8.
Koutras, A. K., Fountzilas G., Makatsoris T., Peroukides S., & Kalofonos H. P. (2010).  Bevacizumab in the treatment of breast cancer.. Cancer Treat Rev. 36(1), 75-82.
Pentheroudakis, G., Kotoula V., De Roock W., Kouvatseas G., Papakostas P., Makatsoris T., et al. (2013).  Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.. BMC Cancer. 13, 49.
Avgerinou, G., Bassukas I., Chaidemenos G., Katsampas A., Kosmadaki M., Kousoulakou H., et al. (2012).  Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece.. BMC Dermatol. 12, 10.
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Bisbinas I., Katsarou A., et al. (2014).  Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.. Osteoporos Int. 25(5), 1633-42.
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Sakellariou G., Savvidis M., et al. (2015).  Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment.. Expert Opin Ther Targets. 19(3), 299-306.
Di Lernia, V., Ricci C., Lallas A., & Ficarelli E. (2014).  Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study.. J Dermatolog Treat. 25(1), 73-4.
Anastasilakis, A. D., Polyzos S. A., Gkiomisi A., Bisbinas I., Gerou S., & Makras P. (2013).  Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.. J Clin Endocrinol Metab. 98(8), 3206-12.
Anastasilakis, A. D., Polyzos S. A., Anastasilakis C. D., Toulis K. A., & Makras P. (2011).  Denosumab and bisphosphonates: rivals or potential "partners"? A "hybrid" molecule hypothesis.. Med Hypotheses. 77(1), 109-11.
Polyzos, S. A., Singhellakis P. N., Naot D., Adamidou F., Malandrinou F. C., Anastasilakis A. D., et al. (2014).  Denosumab treatment for juvenile Paget's disease: results from two adult patients with osteoprotegerin deficiency ("Balkan" mutation in the TNFRSF11B gene).. J Clin Endocrinol Metab. 99(3), 703-7.
Stergiou, P. K., Symeonidis C., & Dimitrakos S. A. (2011).  Descending doses of intravitreal bevacizumab for the regression of diabetic neovascularization.. Acta Ophthalmol. 89(3), 218-21.
Fountzilas, G., Dafni U., Papadimitriou C., Timotheadou E., Gogas H., Eleftheraki A. G., et al. (2014).  Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.. BMC Cancer. 14, 515.
Pavlidis, E. T., Ballas K. D., Symeonidis N. G., Psarras K., Koliakos G., Kouzi-Koliakos K., et al. (2010).  The effect of bevacizumab on colon anastomotic healing in rats.. Int J Colorectal Dis. 25(12), 1465-73.
Mandalos, A., Tsakpinis D., Karayannopoulou G., Tsinopoulos I., Karkavelas G., Chalvatzis N., et al. (2010).  The effect of subconjunctival ranibizumab on primary pterygium: a pilot study.. Cornea. 29(12), 1373-9.
De Roock, W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., et al. (2010).  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.. Lancet Oncol. 11(8), 753-62.
Anastasilakis, A. D., Toulis K. A., Goulis D. G., Polyzos S. A., Delaroudis S., Giomisi A., et al. (2009).  Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis.. Horm Metab Res. 41(10), 721-9.
Sotiriou, E., Apalla Z., Vakirlis E., & Ioannides D. (2009).  Efficacy of adalimumab in recalcitrant hidradenitis suppurativa.. Eur J Dermatol. 19(2), 180-1.
Darwiche, K., Zarogoulidis P., Karamanos N. K., Domvri K., Chatzaki E., Constantinidis T. C., et al. (2013).  Efficacy versus safety concerns for aerosol chemotherapy in non-small-cell lung cancer: a future dilemma for micro-oncology.. Future Oncol. 9(4), 505-25.
Razis, E., Pentheroudakis G., Rigakos G., Bobos M., Kouvatseas G., Tzaida O., et al. (2014).  EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.. J Cancer Res Clin Oncol. 140(5), 737-48.
Triantafyllou, A., Pyrpasopoulou A., Anyfanti P., Balaska E., Aslanidis S., & Douma S. (2013).  eLetter: Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors by M Genovese.. Ann Rheum Dis. 72(5), e7.
Razis, E., Bobos M., Kotoula V., Eleftheraki A. G., Kalofonos H. P., Pavlakis K., et al. (2011).  Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.. Breast Cancer Res Treat. 128(2), 447-56.
Martin, V., Landi L., Molinari F., Fountzilas G., Geva R., Riva A., et al. (2013).  HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.. Br J Cancer. 108(3), 668-75.
Vassilakopoulou, M., Togun T., Dafni U., Cheng H., Bordeaux J., Neumeister V. M., et al. (2014).  In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.. PLoS One. 9(6), e99131.
Androudi, S., Tsironi E., Kalogeropoulos C., Theodoridou A., & Brazitikos P. (2010).  Intravitreal adalimumab for refractory uveitis-related macular edema.. Ophthalmology. 117(8), 1612-6.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.